clinical trials

News

After a phase 2 readout, Sanofi is charting a route to market for AATD therapy efdoralprin alfa, acquired as part of its $2.2bn takeover of Inhibrx.

News

MSD's TROP2-targeting antibody-drug conjugate sac-TMT, licensed from China's Kelun, has improved survival in a late-stage endometrial cancer trial.

News

Novartis has reported new data to support its drive to expand the label of its radioligand therapy Pluvicto in prostate cancer.

News

Regeneron's LAG-3 inhibitor fianlimab has missed the mark in a highly anticipated melanoma trial, hitting its share price.

R&D

Inventus devices and technology solutions have been deployed in 1,000+ clinical trials and are certified in 70+ countries.

News

Biogen will advance its tau-targeting Alzheimer's disease drug diranersen into phase 3, even though it missed the main endpoint in a midstage trial.